• Home
  •  / Champions Oncology

Champions Oncology

OverviewSuggest Edit

Champions Oncology develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company provides Personalized Oncology Solutions that assist physicians in developing personalized treatment options for cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services.

TypePublic
Founded2007
HQHackensack, NJ, USMap
Websitechampionsoncology.com
Employee Ratings2.9More
Overall CultureA-More
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Jul 2019)115(+25%)
Revenue (FY, 2020)$32.1 M(+19%)
Share Price (Jan 2021)$11.5 (+3%)
Cybersecurity ratingBMore

Key People/Management at Champions Oncology

Ronnie Morris

Ronnie Morris

CEO
Philip Breitfeld

Philip Breitfeld

Chief Strategy & Innovation Officer
David Miller

David Miller

Chief Financial Officer
Michael Ritchie

Michael Ritchie

Chief Commercial Officer
Karin Abarca Heidemann

Karin Abarca Heidemann

Vice President of Scientific Operations
Maria Mancini

Maria Mancini

Vice President of Pharmacology
Show more

Champions Oncology Office Locations

Champions Oncology has offices in Hackensack, Rockville and London
Hackensack, NJ, US (HQ)
1 University Plaza Dr #307
Rockville, MD, US
1330 Piccard Dr #025
London, GB
2 Royal College St
Show all (3)

Champions Oncology Financials and Metrics

Champions Oncology Revenue

Champions Oncology's revenue was reported to be $32.12 m in FY, 2020
USD

Revenue (Q2, 2021)

10.1m

Gross profit (Q2, 2021)

4.5m

Gross profit margin (Q2, 2021), %

44.2%

Net income (Q2, 2021)

1.0k

EBIT (Q2, 2021)

7.0k

Market capitalization (19-Jan-2021)

154.1m

Closing stock price (19-Jan-2021)

11.5

Cash (31-Oct-2020)

8.6m

EV

152.1m
Champions Oncology's current market capitalization is $154.1 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

7.1m8.3m11.6m8.9m11.2m15.4m20.2m27.1m32.1m

Revenue growth, %

(23%)26%

Sales and marketing expense

2.9m2.7m3.2m4.3m3.4m3.3m2.6m3.1m4.2m

General and administrative expense

5.5m4.6m6.1m5.3m5.2m5.0m4.1m4.7m6.6m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Revenue

1.6m1.7m2.4m2.1m1.5m2.9m3.0m2.4m3.7m1.9m1.9m1.8m2.8m3.0m2.6m3.7m4.5m3.6m5.0m5.2m5.1m6.2m6.7m6.4m6.7m7.6m9.0m9.5m10.1m

Cost of goods sold

3.1m3.5m3.4m3.8m3.9m4.3m5.3m5.6m

Gross profit

3.1m3.2m3.0m3.0m3.7m4.7m4.2m4.5m

Gross profit Margin, %

50%48%47%44%49%52%44%44%
show all
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

4.8m9.6m5.9m9.4m3.3m856.0k3.2m8.3m

Accounts Receivable

584.0k500.0k1.3m1.1m1.3m2.3m3.9m4.4m4.8m

Prepaid Expenses

205.0k315.0k383.0k346.0k300.0k287.0k308.0k385.0k

Inventories

443.0k
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Cash

8.8m7.1m6.5m2.9m2.2m10.8m7.4m7.6m5.8m3.1m575.0k182.0k6.8m4.2m3.3m4.5m4.3m3.5m400.0k700.0k1.1m1.0m2.0m3.3m2.2m2.8m3.3m6.9m8.6m

Accounts Receivable

1.2m832.0k497.0k639.0k627.0k642.0k1.8m1.5m3.1m925.0k1.1m1.1m1.5m1.9m2.1m1.6m1.9m2.0m2.7m2.6m2.9m3.8m4.7m3.9m3.9m3.9m4.5m5.0m6.0m

Prepaid Expenses

341.0k328.0k110.0k208.0k95.0k300.0k255.0k219.0k281.0k456.0k393.0k258.0k366.0k295.0k414.0k349.0k445.0k541.0k360.0k303.0k185.0k246.0k262.0k298.0k256.0k363.0k355.0k360.0k477.0k

Current Assets

10.9m8.8m7.6m3.8m2.9m11.7m9.4m9.3m9.2m4.4m2.1m1.5m8.6m6.3m5.8m6.4m6.7m6.1m3.5m3.5m4.2m5.0m6.9m7.5m6.3m7.1m8.1m12.3m15.0m
show all
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(8.7m)(6.3m)(7.4m)(13.1m)(10.4m)(1.5m)128.0k(2.0m)

Depreciation and Amortization

105.0k203.0k213.0k214.0k156.0k168.0k360.0k606.0k825.0k

Accounts Payable

96.0k(472.0k)(223.0k)433.0k482.0k(43.0k)301.0k653.0k333.0k

Cash From Operating Activities

(5.2m)(4.3m)(3.4m)(9.6m)(6.5m)(2.8m)(1.2m)1.9m2.9m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Net Income

(2.0m)(4.4m)(6.1m)(1.3m)(3.3m)(4.3m)(2.2m)(4.6m)(5.1m)(3.5m)(6.7m)(9.5m)(2.9m)(5.5m)(7.9m)(2.5m)(3.1m)(4.5m)(674.2k)(768.5k)(844.0k)482.0k750.0k381.0k(641.0k)(334.0k)72.0k75.0k76.0k

Depreciation and Amortization

29.0k49.0k65.0k54.0k103.0k153.0k50.0k102.0k158.0k56.0k110.0k166.0k37.0k76.0k114.0k45.0k87.0k127.0k42.0k132.0k253.0k118.0k269.0k433.0k182.0k360.0k579.0k277.0k584.0k

Accounts Payable

(82.0k)(286.0k)43.0k(385.0k)(467.0k)(574.0k)(227.0k)(220.0k)(266.0k)347.0k651.0k381.0k22.0k(76.0k)101.0k(387.0k)(744.0k)(572.0k)(120.0k)(303.0k)124.0k(43.0k)(141.0k)(46.0k)(82.0k)(341.0k)(913.0k)(465.0k)568.0k

Cash From Operating Activities

(1.5m)(3.3m)(3.7m)(1.8m)(2.6m)(3.1m)(2.1m)(1.9m)(3.6m)(2.8m)(5.2m)(7.6m)(2.5m)(5.1m)(5.9m)(2.4m)(2.6m)(3.2m)(1.9m)(1.7m)(1.2m)336.0k400.0k1.6m(279.0k)81.0k360.0k(715.0k)164.0k
show all
USDQ1, 2012

Financial Leverage

-11.9 x
Show all financial metrics

Champions Oncology Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

Learn more about our premium products
SecurityScorecard logo

Champions Oncology Online and Social Media Presence

Champions Oncology's Trends

Embed Graph

Champions Oncology Company Culture

  • Overall Culture

    A-

    86/100

  • CEO Rating

    A-

    80/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Champions Oncology News and Updates

December 10, 2018

Champions Oncology to Announce Second Quarter Financial Results on Monday, December 17, 2018

HACKENSACK, N.J., Dec. 10, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and...
September 13, 2018

Champions Oncology Reports Record Quarterly Revenue of $6.2 Million

HACKENSACK, N.J., Sept. 13, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its financial results for the first...
September 13, 2018

Champions Oncology to Participate at the Janney Montgomery Scott Healthcare Conference 2018 in New York

HACKENSACK, N.J., Sept. 13, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced that management will participate at...
July 26, 2018

Champions Oncology Reports Record Annual Revenue Exceeding $20M for Fiscal Year Ended April 30, 2018

HACKENSACK, N.J., July 26, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the fourth fiscal quarter...

Champions Oncology Blogs

January 21, 2021

Colorectal Cancer and the Benefits of Immuno-Oncology

Colorectal cancer (CRC) is a leading cause of cancer deaths globally. Advances in early detection have improved survival rates, but patients diagnosed with metastatic CRC still have stubbornly poor 5-year survival rates. Standard treatments for CRC include surgery, chemotherapy, and radi…
January 19, 2021

Champions Oncology Announces Partnership with Code Ocean to Expand the Functionality of Lumin Bioinformatics

HACKENSACK, NJ – January 19, 2021 9AM - Champions Oncology, Inc. (Nasdaq: CSBR), a leading global oncology technology company that is transforming drug discovery and development through data-driven research strategies, announced today a partnership with Code Ocean to expand the functiona…
January 14, 2021

Ask the Expert – Improving Oncology Drug Development Strategies

Alex Moreau, PhD, from Champions Oncology answers key questions about Drug Development Strategies 1) Do you have patient response correlating to the PDX?Yes. We demonstrated that PDX models effectively capture responses to oncology therapy in a heterogeneous cohort of patients with so…
January 07, 2021

Prognostic Indices in Chronic Lymphocytic Leukemia (CLL)

The management and treatment of patients with chronic lymphocytic leukemia (CLL) has improved greatly in recent years due to new insights in genetic and molecular factors that contribute to disease progression. Clinical staging systems were first developed more than 40 years ago and incl…
January 05, 2021

Champions Oncology Announces the Expansion of Lumin Bioinformatics: Now Featuring a Highly Valuable Set of Proteomic Data and Analytics

HACKENSACK, NJ – January 5, 2021 8:30AM - Champions Oncology, Inc. (Nasdaq: CSBR), a leading global oncology technology company that is transforming drug discovery and development through data-driven research strategies, announced today the expansion of its SaaS program, Lumin Bioinforma…
December 22, 2020

The Pros & Cons: Syngeneic mouse models with human drug targets

A wide range of mouse models are currently available to researchers working on the preclinical development of oncology therapeutics. Syngeneic mouse models, also known as allograft mouse tumor models, are mice engrafted with mouse-derived cancer cell lines. These mice have an intact muri…
Show more

 Champions Oncology Frequently Asked Questions

  • When was Champions Oncology founded?

    Champions Oncology was founded in 2007.

  • Who are Champions Oncology key executives?

    Champions Oncology's key executives are Ronnie Morris, Philip Breitfeld and David Miller.

  • How many employees does Champions Oncology have?

    Champions Oncology has 115 employees.

  • What is Champions Oncology revenue?

    Latest Champions Oncology annual revenue is $32.1 m.

  • What is Champions Oncology revenue per employee?

    Latest Champions Oncology revenue per employee is $279.3 k.

  • Who are Champions Oncology competitors?

    Competitors of Champions Oncology include Gene Techno Science, Rgenta and Rubicon Biotechnology.

  • Where is Champions Oncology headquarters?

    Champions Oncology headquarters is located at 1 University Plaza Dr #307, Hackensack.

  • Where are Champions Oncology offices?

    Champions Oncology has offices in Hackensack, Rockville and London.

  • How many offices does Champions Oncology have?

    Champions Oncology has 3 offices.